论文部分内容阅读
为验证合用乙肝特异性转移因子、肝康灵和盐酸左旋咪唑涂布剂治疗无症状乙型肝炎病毒携带者（ＡＳＣ）的疗效，对治疗Ⅰ组３８例“大三阳”和治疗Ⅱ组９７例“小三阳”使用上述三种药物合用；对照Ⅰ组２８例“大三阳”和对照Ⅱ组５５例“小三阳”采用肝泰乐、维生素Ｃ和１０％葡萄糖液静脉点滴。结果：治疗Ⅰ组和对照Ⅰ组近期ＨＢｅＡｇ阴转率分别为５５．３％和１４．３％，远期分别为６８．４％和１０．７％。ＨＢＶ－ＤＮＡ阴转率：治疗Ⅰ组、治疗Ⅱ组、对照Ⅰ组和Ⅱ组的近期疗效分别为３９．５％、６９．１％、１０．７％和１０．９％；远期疗效别为４７．４％、７３．２％、７．１％和１４．５％。治疗Ⅱ组和治疗Ⅰ组相比，治疗Ⅱ组和对照Ⅱ组相比，无论近期还是远期疗效，ＨＢＶ－ＤＮＡ转阴转率均有非常显著性差异（Ｐ＜０．０１。）治疗Ⅰ组和对照Ⅰ相比，ＨＢｅＡｇ阴转率和ＨＢＶ－ＤＮＡ阴转率均有非常显著性差异（Ｐ＜０．０１）。提示：本疗法治疗ＡＳＣ可使ＨＢｅＡｇ、ＨＢＶ－ＤＮＡ阴转，抑制ＨＢＶ－ＤＮＡ复制，以治疗Ⅱ组疗效为优；且本疗法可提高机体抵抗力，无不良反应，价格适宜，推荐使用本疗法治疗无症状ＨＢＶ携带者。
In order to verify the efficacy of combination of hepatitis B-specific transfer factor, heparin and levamisole hydrochloride in the treatment of asymptomatic hepatitis B virus carriers (ASC), 38 cases of “Sanyangyang” and 97 cases of treatment groupⅠ In the control group, 28 cases of “Sanyangyang” and control group Ⅱ, 55 cases of “Sanyangyang” were treated with GTA, Vitamin C and 10% glucose intravenously. Results: The negative conversion rates of HBeAg in the treatment group Ⅰ and control group Ⅰ were 55.3% and 14.3%, respectively, and 68.4% and 10.7% respectively in the long term. The negative conversion rate of HBV-DNA was 39.5%, 69.1%, 10.7% and 10.9% in the treatment group Ⅰ and group Ⅱ, respectively. The long-term effects 47.4%, 73.2%, 7.1% and 14.5%. There was a significant difference (P <0.01) in the negative conversion rate of HBV-DNA between treatment group Ⅱ and treatment group Ⅰ in treatment group Ⅱ and control group Ⅱ, both short-term and long-term effects There was a significant difference between the negative rate of HBeAg and the negative rate of HBV DNA in group Ⅰ and group Ⅰ (P <0.01). Tip: The treatment of ASC can HBeAg, HBV-DNA overcast, inhibition of HBV-DNA replication, the treatment group Ⅱ effect is excellent; and the therapy can improve the body resistance, no adverse reactions, the price is appropriate, the recommended use of the therapy Treatment of asymptomatic HBV carriers.